Erythema Multiforme
Learn about Erythema Multiforme (EM), including EM Major and EM Minor, diagnosis, clinical documentation, and medical coding. Find information on Erythema Multiforme symptoms, causes, treatment, and ICD-10 codes for accurate healthcare records and billing. This resource provides essential guidance for clinicians and healthcare professionals on properly documenting and coding EM in medical settings.
An acute, self-limiting, inflammatory skin reaction, often triggered by infections or medications.
Target-like lesions, blisters, and/or mucosal involvement. May have fever or malaise.
Outpatient, Dermatology, Infectious Disease or Allergy clinics. Hospitalization in severe cases (EM major).
ICD-10 Code Families
Complete code families applicable to L51.9
When to use each related code
| Description | When to use |
|---|---|
| Acute, immune-mediated skin reaction. | Target-like lesions present, often following HSV infection. Consider drug reactions. |
| Severe mucocutaneous reaction with epidermal detachment. | Widespread blisters and erosions, positive Nikolsky sign. Code only for severe cases involving >30% BSA. |
| Mild form of Erythema Multiforme. | Localized target-like lesions without mucosal involvement. Often follows HSV infection. |
Best-practice checklist
- ✓Document target-like lesions or macules/papules.
- ✓Describe lesion distribution (acral, truncal, oral).
- ✓Note mucosal involvement (oral, genital, ocular).
- ✓Record presence/absence of systemic symptoms (fever, malaise).
- ✓Specify EM subtype (minor, major, SJS/TEN overlap).
Common pitfalls to avoid
Incorrectly coding EM Major as EM Minor or vice versa, impacting reimbursement and quality metrics. CDI crucial for specificity.
Lack of documentation linking EM to underlying cause (e.g., HSV, medication) leads to coding and billing errors. Crucial for medical necessity.
Misdiagnosing overlapping SJS/TEN as EM, leading to incorrect, lower severity coding and affecting quality reporting and outcomes analysis.
Best-practice tips
- 01Discontinue causative drug (ICD-10-CM L51.1, CDI: Document reaction onset)
- 02Topical corticosteroids for localized lesions (SNOMED CT 70618009, RxNorm: 649752)
- 03Oral antihistamines for itching relief (ICD-10-CM L51.0, optimize coding)
- 04Cool compresses, bland emollients soothe skin (patient education, compliance)
- 05Severe EM: Systemic corticosteroids (SNOMED CT 390008001, justify use in documentation)
Step-by-step checklist
- 1
1. Confirm target-like lesions or macules/papules. ICD-10: L51.1 Document morphology.
- 2
2. Assess mucosal involvement (EM major) or absence (EM minor). ICD-10: L51.0, L51.2
- 3
3. Rule out herpes simplex virus (HSV) or Mycoplasma pneumoniae infection. Document triggers.
- 4
4. Evaluate for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) overlap. Careful DDX.
Ready-to-paste narrative
Patient presents with symptoms consistent with Erythema Multiforme (EM), likely EM minor. Onset of the rash was reported as [duration] ago, characterized by [description of lesions - e.g., well-defined, erythematous target lesions, macules, papules, vesicles, bullae] distributed on [location of lesions - e.g., extremities, palms, soles, oral mucosa]. Patient denies fever, malaise, or systemic symptoms. Lesions are [description of discomfort - e.g., pruritic, painful, burning]. No mucosal involvement noted. Patient reports [possible triggering factor - e.g., recent herpes simplex virus infection, medication exposure, Mycoplasma pneumoniae infection]. Differential diagnoses considered include Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug eruption, and urticaria. Based on clinical presentation and history, the diagnosis of Erythema Multiforme minor is favored. Treatment plan includes [treatment - e.g., symptomatic management with antihistamines, topical corticosteroids, discontinuation of suspected causative medication]. Patient education provided regarding EM prognosis, recurrence prevention, and potential complications. Follow-up scheduled in [duration] to monitor resolution and assess for any progression of symptoms. ICD-10-CM code L51.1 (Erythema multiforme) is assigned.
Common questions and answers
How can I differentiate between erythema multiforme minor and erythema multiforme major (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis overlap) in my clinical practice?+
Differentiating erythema multiforme (EM) minor from EM major, which represents the milder end of the Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) spectrum, requires careful assessment of mucosal involvement and skin detachment. EM minor typically presents with target lesions and limited or no mucosal involvement. While oral lesions may occur, they are usually mild. In contrast, EM major involves more widespread and severe mucosal erosions affecting at least two mucosal sites (e.g., oral, ocular, genital). Additionally, EM major exhibits epidermal detachment affecting less than 10% of the body surface area (BSA). Skin biopsies can be helpful in ambiguous cases. Explore how histopathological findings can further aid in distinguishing these conditions. Consider implementing a standardized skin assessment protocol in your practice to accurately document the extent of skin and mucosal involvement for appropriate diagnosis and management.
What are the most common drug triggers for erythema multiforme, and how should I approach medication management in a patient with suspected drug-induced EM?+
Several medications are commonly implicated in erythema multiforme (EM) reactions. These include sulfonamides, anticonvulsants (e.g., phenytoin, carbamazepine, lamotrigine), nonsteroidal anti-inflammatory drugs (NSAIDs), allopurinol, and certain antibiotics (e.g., penicillins, cephalosporins). If drug-induced EM is suspected, the offending medication should be immediately discontinued. A thorough medication history is crucial. Learn more about the Naranjo Algorithm and other causality assessment tools to help determine the likelihood of a drug being the causative agent. If the patient requires alternative medications for their underlying condition, careful consideration should be given to potential cross-reactivity within drug classes. Consider implementing a phased reintroduction of medications under close observation when necessary.
What are the evidence-based treatment options for erythema multiforme, and how do I tailor treatment based on the severity of symptoms?+
Treatment for erythema multiforme (EM) depends largely on the severity of the reaction. For mild cases of EM minor, symptomatic management with topical corticosteroids, oral antihistamines for pruritus, and analgesics for pain may suffice. Oral corticosteroids may be considered in more extensive cases or if symptoms are severe. In cases of EM major with significant mucosal involvement or skin detachment, supportive care becomes paramount. This includes fluid and electrolyte management, wound care, pain control, and ophthalmologic evaluation for ocular involvement. Explore how intravenous immunoglobulin (IVIG) has been studied in severe EM and SJS/TEN overlap to potentially modulate the immune response. Learn more about the role of systemic corticosteroids in severe cases and the ongoing debate surrounding their efficacy.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.